Additional Study Information: This is a phase 3 clinical trial to determine the efficacy of topical SGX301 (synthetic hypericin) in combination with visible light therapy on cutaneous T-cell lymphoma (CTCL). Selected subjects can participate in 3 cycles each consisting of a 6 week treatment period where a chosen lesion will be treated with the study ointment (twice a week) followed by light therapy the next day. All subjects will be seen monthly after their last treatment for 6 month to assess for any lesional changes. The study will include 2 skin biopsies and blood collections which will be used to measure the safety and efficacy of the drug. The study duration is approximately 1 year.